KLOW Results in the Research Literature

The short version

When people ask about KLOW results, they are asking about the combined effect of four peptides whose individual studies run in different directions. This page surfaces those results honestly — one arm at a time, with every number attributed to its study and species.

The brightest single result in the KLOW literature belongs to the TB-500 arm: thymosin beta-4 (the full-length native protein related to TB-500) increased wound re-epithelialization — the regrowth of skin surface cells — by 61% at seven days in rat full-thickness wound models ^[1]. That number is real. It is a finding about thymosin beta-4 in rats. It is not a finding about the KLOW blend.

BPC-157 accelerated healing of fully transected rat Achilles tendons across every measure tested ^[2]. GHK-Cu shifted gene expression in fibroblasts toward collagen synthesis and matrix repair and showed statistically significant hair improvement in a human topical study ^[4][5][8]. KPV suppressed inflammatory signaling at nanomolar concentrations and reduced colitis severity in mice ^[3].

KLOW results = the sum of four separate literatures. The combination has never been tested. That gap is noted on every page.

TB-500 arm: re-epithelialization and wound closure

The wound-reepithelialization lens is the most precisely measured outcome in this body of literature. In a rat full-thickness wound model, topical or intraperitoneal thymosin beta-4 produced the following versus saline: re-epithelialization increased 42% at four days and up to 61% at seven days; wound contraction rose by at least 11% by day seven; collagen deposition increased; angiogenesis increased ^[1]. At the cellular level, as little as 10 picograms of thymosin beta-4 stimulated keratinocyte (skin surface cell) migration 2-3-fold in culture — the effect is measurable at extraordinarily low concentrations ^[1].

X-ray crystallography (2 angstrom resolution) established that thymosin beta-4 forms a 1:1 complex with G-actin (monomeric actin, the cytoskeletal building block) and sequesters it by capping both ends, preventing polymerization ^[11]. This is the structural mechanism underlying cell migration: by buffering the actin monomer pool, thymosin beta-4 controls the local supply of actin available for the leading edge of a moving cell. That leading edge is what closes a wound.

A 2004 multi-endpoint study demonstrated concurrent angiogenesis, wound healing and hair follicle activation in rodents ^[9]. A 2025 review of pro-resolving pathways characterized the mechanism as running through specialized resolution mediators, not solely through cytokine suppression ^[13].

Critical distinction: TB-500 is the short N-acetylated heptapeptide Ac-LKKTET-Q, corresponding to the LKKTET actin-binding motif of the 43-amino-acid native protein. Most foundational efficacy data — including the +42%/+61% re-epithelialization figures — are for full-length native thymosin beta-4, not the TB-500 fragment. A 2026 Sports Medicine review flagged this gap and noted that rigorous human safety data for unapproved musculoskeletal peptides, including TB-500/thymosin beta-4, remain scarce ^[7].

BPC-157 arm: tendon and tissue repair

BPC-157 (Body Protection Compound 157, CAS 137525-51-0, MW 1419.53 Da) is a synthetic 15-amino-acid peptide derived from a partial sequence of a protein identified in human gastric juice. In the tissue-repair literature, it has the most extensive rodent evidence in the blend.

In the index study for tendon repair: BPC-157 accelerated healing of a fully transected rat Achilles tendon across biomechanical measures, functional recovery, microscopic collagen organization and macroscopic appearance, and stimulated tendocyte (tendon cell) outgrowth in vitro ^[2]. The doses studied ranged from 10 micrograms to 10 nanograms to 10 picograms per rat, administered intraperitoneally once daily or locally — the effect was present across this wide dose range.

The mechanism runs through the VEGFR2/PI3K/Akt/eNOS angiogenic pathway (VEGFR2 is the main receptor for vascular endothelial growth factor, driving new blood vessel formation), upregulation of the growth-hormone receptor in tendon fibroblasts, and a nitric-oxide system effect partly resistant to L-NAME (a standard nitric oxide inhibitor), suggesting an additional signaling route.

Human data is limited. A 2025 first-in-human intravenous safety pilot administered BPC-157 up to 20 mg in two healthy adults (10 mg on day one, 20 mg on day two, in 250 mL saline as a one-hour infusion). No adverse events were observed and no measurable changes were seen in cardiac, hepatic, renal, thyroid or glucose biomarkers ^[6]. Two participants; not an efficacy trial. The 2025 Sikiric et al. review placed BPC-157 in a broader safety and pharmacological context ^[12].

GHK-Cu arm: collagen, gene expression and skin

GHK-Cu (Glycyl-L-Histidyl-L-Lysine copper complex, CAS 89030-95-5, MW 402.92 Da) is the mass-dominant component of the canonical KLOW vial at 50 mg of the 80 mg total. First isolated from human plasma by Loren Pickart in 1973, it is the most extensively studied of the four constituents in clinical and near-clinical settings.

A 2015 review catalogued its canonical skin-regeneration evidence: GHK-Cu stimulates synthesis of collagen, dermatan sulfate, chondroitin sulfate and the proteoglycan decorin; topical formulations increased collagen production in 70% of treated women versus 50% for vitamin C and 40% for retinoic acid; and plasma GHK declines from approximately 200 ng/mL at age 20 to approximately 80 ng/mL by age 60 ^[4].

A 2018 bioinformatic study using Connectivity Map analysis found that GHK modulates expression of approximately 31% of human protein-coding genes at a 50%-or-greater change threshold, increasing expression of 59% of affected genes and suppressing 41%, with the strongest signals on extracellular-matrix remodeling, ubiquitin-proteasome protein quality control, antioxidant defense, and DNA-repair gene sets ^[5].

In a controlled human trial: a topical complex of 5-aminolevulinic acid and GHK peptide (ALAVAX) in 45 men with androgenetic alopecia (pattern hair loss) increased hair count by 52.6 (100 mg/mL formulation) and 71.5 (50 mg/mL formulation) versus 9.6 for placebo (p<0.05) over six months, with no adverse events ^[8]. This is the strongest controlled human efficacy signal for a GHK-containing topical in the KLOW literature.

GHK-Cu liposomes accelerated scald-wound healing in mice and increased human endothelial cell proliferation by 33.1% versus controls, upregulating VEGF, FGF-2, CDK4 and CyclinD1 ^[10] — an angiogenic signal that overlaps mechanistically with the BPC-157 arm.

KPV arm: anti-inflammatory signaling and gut selectivity

KPV (Lys-Pro-Val, CAS 67727-97-3, MW 342.44 Da) is the C-terminal tripeptide of alpha-melanocyte-stimulating hormone (alpha-MSH). It is the anti-inflammatory and immune-modulating arm of the blend.

The defining mechanistic study established two things: that KPV is a substrate of the PepT1 di/tripeptide transporter (SLC15A1) with a Km of approximately 160 micromolar, giving it gut-selective uptake via a transporter that is upregulated in inflamed intestinal epithelium; and that at nanomolar concentrations, KPV inhibits NF-kappaB p65/RelA nuclear import and MAP-kinase ERK/p38 activation in human intestinal epithelial cells and immune cells, reducing TNF-alpha, IL-6 and IL-1beta secretion ^[3]. In DSS- and TNBS-induced colitis mouse models, oral KPV at 100 micromolar in drinking water reduced disease severity ^[3].

No controlled KPV monotherapy trial has reached clinical approval. Human data are restricted to early delivery pilots. The PepT1 uptake mechanism gives KPV a degree of anatomical selectivity — the transporter concentrates uptake in tissues where inflammation increases PepT1 expression — which distinguishes it mechanistically from the other three components in the blend.

The unlit region: no controlled blend study exists

Four lights in the dark. And one region that does not glow.

No controlled in-vivo or human study has tested the four-peptide KLOW blend against monotherapy, against any subset, or against placebo. This is not a gap that will be filled by re-reading the component literature — it is a structural absence in the experimental record.

Furthermore, the four constituents have markedly different reported half-lives. BPC-157 has a very short elimination half-life; the tripeptides KPV and GHK-Cu clear even faster; and the TB-500 heptapeptide fragment has different pharmacokinetics from native thymosin beta-4. A single co-formulated vial cannot hold all four components at matched peak exposures. Whatever combination rationale exists is mechanistic extrapolation, not pharmacokinetic or pharmacodynamic data about the blend.

The klow results here are four separate component results. They are the best available evidence. They are not KLOW results in the sense of outcomes for the combination.